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INTRODUCTION 
 
   Joint involvement is the most common extra intestinal involvement in inflammatory 
bowel disease (IBD) and occurs in 10-20 % of the patients. Peripheral involvement is 
pauciarticular, asymmetrical, non-deforming, transitory and migratory synovitis and or 
arthritis. Peripheral enthesiopathies can occur at Achilles tendon and at the insertion of 
fascia plantaris. Axial involvement can vary from asymptomatic sacroiliitis to classic 
ankylosing spondylitis .The true prevalence of axial involvement is not known as the 
onset is insidious. There is parallelism between the flare up/remission of bowel 
symptoms and arthritis suggesting a similar etiopathogenesis. Inflammatory peripheral 
arthropathy is similar to the reactive arthritis that occur secondary to certain intestinal 
infections. Reactive arthritis is secondary to a small set of intracellular, aerobic, invasive 
gram negative bacteria and is dependent on specific properties of the bacterium. The 
temporal profile of the gut and joint inflammation suggests the involvement of the bowel 
bacterial flora. However, the definite profile of the flora responsible for this is not known. 
Chronically disabled persons can disorganize the life of the entire family and disrupt the 
existing balance between them. Joint manifestations leading to disability impairs the 
patient’s quality of life and is a burden to the family.  
 
IBD is an inflammatory condition of the bowel; a clinically heterogenous disorder with 
the potential for systemic involvement. A wide clinical spectrum may be observed 
including tendinitis, enthesopathy, peripheral arthritis, axial arthritis (sacroiliitis) or a 
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combination of these complications. Patients with IBD presenting with inflammatory 
back pain and /or peripheral arthritis are classified as spondyloarthropathy. Inflammation 
of the colon (ulcerative colitis or Crohn’s colitis) leads to joint manifestations in 26-39% 
of patients, whereas patients with Crohn’s ileitis develop joint manifestations in only 
14%; this reflects the importance of the colonic bacteria in the causation of arthritis. 
Inflammatoy bowel disease is believed to result from an abnormal immune reaction to 
luminal bacteria in a genetically predisposed host. In addition to host immune and genetic 
factors, the luminal bacteria are also considered to be important. Bacteria in the intestine 
probably prime immune cells that then circulate to the joints and damage them. While 
several investigators have described differences in the intestinal microbial flora between 
patients with IBD and healthy individuals, it is not known whether IBD patients with 
arthritis have a different flora from IBD patients without arthritis. We know little about 
the pattern of joint involvement in IBD in India and how disabling it is to the person who 
suffers from IBD. It would be interesting to know this because the genetic background of 
Indians is probably different from Caucasians where the data is available and we know 
that the course of disease in Indians is probably different, eg., less commonly leading to 
cancer. We therefore proposed to study the prevalence of joint disease in patients with 
IBD, to document its pattern, and to determine whether the gut bacteria of patients with 
joint involvement are different from those of patients without joint involvement. 
 
 
 
 
 
 9
                                                  ABSTRACT 
 
 
TITLE OF THE ABSTRACT:  Joint manifestations in Inflammatory Bowel Disease 
(IBD) – A cross-sectional study with special emphasis on relationship of gut flora to 
bowel and joint disease 
DEPARTMENT: Gastrointestinal Sciences 
NAME OF THE CANDIDATE: Dr Avinash B 
DEGREE AND SUBJECT: Doctor of Medicine (D.M) Medical Gastroenterology 
NAME OF THE GUIDE: Dr B S Ramakrishna. DM, Professor and Head, Clinical 
Gastroenterology and Hepatology, Department of Gastrointestinal Sciences, Christian 
Medical College, Vellore 
OBJECTIVES : To assess the frequency and pattern of joint involvement in 
inflammatory bowel disease and to determine whether joint involvement is associated 
with a dysbiosis of the intestinal microbial flora  
METHODS:  Consecutive patients with ulcerative colitis (UC) or Crohn's disease (CD) 
were prospectively interviewed and examined by the principal investigator and clinical 
details and laboratory results noted. The pattern of joint involvement and severity was 
independently confirmed by a specialist rheumatologist. Radiographs of the involved 
peripheral joints, sacroiliac joints and spine were obtained. DNA was extracted from 
stool samples and real time PCR targeting 16S ribosomal DNA was used to quantitate 
specific classes of “beneficial” (Clostridium coccoides, bifidobacteria, and lactobacilli) 
and “aggressive” (Bacteroides, Enterobacteriaceae, Enterococcus) bacterial flora. Disease 
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activity and bacterial counts were compared between patients with and without joint 
involvement.  
RESULTS : Sixty eight patients with ulcerative colitis (UC) and 60 with Crohn's disease 
(CD) were included in this prospective study. Arthritis was noted in twenty- four IBD 
patients (18 %); 13 with CD (21.6%) and in 11 with UC (16.1%).  Peripheral arthritis 
alone was noted in 12 patients, axial involvement alone in 7 and rest had mixed pattern. 
The most prevalent phyla in IBD patients were Bacteroidetes and Bifdobacterium.. 
Enterobacteriaceae were significantly higher in patients with UC than in CD.  In UC 
patients, joint involvement was associated with higher Enterococcus species and lower 
Clostridium coccoides  suggesting a dysbiosis in these patients. 
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                         OBJECTIVES AND AIMS OF STUDY  
 
 
The overall aim of this study was to assess the frequency and pattern of joint involvement in 
Indian patients with inflammatory bowel disease and to determine whether specific classes of 
the intestinal microbial flora of IBD patients with arthritis was quantitatively different from 
that of IBD patients without arthritis. The specific objectives were as follows: 
 
• To study the prevalence, pattern and disability resulting from joint disease in 
patients of inflammatory bowel disease in India. 
 
• To study the pattern of bacterial flora of the gut in patients with IBD and 
arthritis and to compare this with the pattern in patients with IBD but without 
arthritis. 
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                              REVIEW OF LITERATURE                          
 
History: 
The first author to report the association between arthritis and Ulcerative Colitis (UC) 
was White in 1895 while the first report of joint disease in Crohn’s Disease (CD) may be 
described by Abercrombie in 1930. Both were post mortem examination findings in 
patients of arthritic symptoms (Jan tore gran et al). The association between disease of 
bowel and musculoskeletal symptoms was recognized since 1900. In 1920, Rea Smith 
described bowel infection was responsible for rheumatism and to treat rheumatic 
complaints he performed partial colectomy in 68 patients. Hench described peripheral 
joint arthritis associated with chronic ulcerative colitis in 1935. He had noted flares of 
arthritic symptoms with colitic flares. In 1959, Wigut and Watkinson described arthritis 
associated with inflammatory bowel disease (IBD) (Gravallese et al). It was believed that 
colonic stasis be it anatomic or functional in origin fostered bacterial fermentation which 
produced arthritis. The current opinion favors the concept of enteric organisms acting as 
bowel triggers in disease susceptible individuals (Jan tore gran et al) 
  IBD is divided into two major clinical pathologic subtypes – Ulcerative Colitis 
(UC) and Crohns Disease (CD). The articular complications of each are considered 
identical. Joint disease is the most common extraintestinal features of IBD.  A wide 
spectrum of joint manifestations have been observed in IBD including tendonitis, 
enthesopathy, peripheral (non deforming) arthritis, axial arthritis (sacroilitis) or a 
combination of these complications. (Peter et al).  
Epidemiology: 
 13
Prevalence of UC ranges from 50 – 100 per 100000 in the general population. Prevalence 
of CD has been increasing during the last few decades to about 75 per 100000. In a 
screening study for colorectal cancer involving 37000 individuals without intestinal 
symptoms the combined prevalence of UC and CD was 56 per 100000 whereas the 
prevalence of symptomatic IBD is estimated as 90-150 per 100000 (Mayberry et al) . The 
reported incidence of enteropathic arthritis in IBD varied among authors.  In the original 
monograph on Crohn’s disease only brief mention of arthritis is made as a complication. 
Earlier studies suggested that arthritis was noted commonly in UC than in CD but more 
recent studies suggest the opposite. Farmer et al studied a cohort of patients with CD 
strictly defined into small intestinal, ileocolonic and colonic involvement at the time of 
initial presentation. Peripheral arthritis was seen in 16% of patients with colonic 
involvement compared with 4% of those with small intestinal involvement and 3.6% with 
ileocolonic involvement. Of patients with CD, those with colonic involvement alone had 
the highest incidence of peripheral arthritis. The axial arthropathy in CD is identical to 
that in UC in frequency of occurrence and in clinical manifestations. The reported 
incidence of spondylitis in association with IBD varies from 1.1% to 6.4%. Dekker Saeys 
et al studied 109 consecutive patients with IBD along with extensive rheumatologic 
examination of all patients and noted that spondylitis was present in 3.7% of the cases. 
Arthritis is the most common extra intestinal manifestation of IBD and appears in 2-20% 
of patients with either UC or CD. The frequency of peripheral arthritis in IBD ranges 
from 17-20% of patients with a higher prevalence in CD. (Gravallese et al) 
In an extensive retrospective study in an Oxford IBD clinic involving 1459 
patients with IBD, peripheral arthritis was described in 6% of UC and 10% of CD. 
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(Orchard et al)  In a study from gastrointestinal clinic, actual synovitis was noted in 10% 
of IBD patients, enthesitis in 7% and 29% of patients reported a history of swollen joints. 
Axial involvement occurs in both the diseases. The true prevalence of sacroilitis in IBD is 
unclear as the onset is usually insidious. Thirty percent of patients with IBD had 
inflammatory back pain, 1/3rd of patients had unilateral or bilateral sacroilitis (SI) stage II 
and in 18% of patients SI was asymptomatic.  Kochhar et al in a prospective study of 150 
IBD patients noted radiological sacroilitis in 14%, peripheral arthritis in 10.7% without a 
single case of spondylitis. This was in contrast with other Indian studies that had reported 
fewer incidences of extraintestinal features in the Indian population.  (R Kochhar et al). 
Polyarticular destructive arthritis and unilateral sacroilitis may also be manifestations of 
CD (Norton et al) 
The spondyloarthropathies and IBD likely involve a poorly understood interaction 
of genetic and environmental factors. Common features include a genetic predisposition, 
a triggering antigen, and an abnormal immune response ( Joseph McKinley et al) 
 
Evidence of Gut-Joint Enteropathy in peripheral arthritis 
Inflammatory peripheral arthropathy in IBD is similar to reactive arthritis secondary to 
intestinal infection. In the latter, aerobic invasive Gram negative bacteria e.g. Shigella 
flexneri, Salmonella typhimurium, Yersinia enterocolitica and Campylobacter jejuni are 
the possible etiological agents. However other organisms with similar invasive properties 
such as enteroinvasive Escherichia coli have shown no relation with reactive arthritis.  
These observations indicate that the specific properties of the bacterium are important. 
The clinical observation of parallelism between the flare up of CD and peripheral arthritis 
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suggests a similar etiopathogenesis. There is no data on the presence of bacterial DNA 
/RNA/ degradation products in the synovium. The best evidence of bacterial role of the 
arthritis in IBD comes from transgenic rats in which colitis and arthritis develop only 
after restoration of gut flora. (De Vos et al)  
Exacerbations of bowel disease and flares of peripheral arthritis tend to coincide 
in both UC and CD. Greenstein et al showed that the incidence of peripheral arthritis 
tends to be higher in patients with CD than in UC. Of patients with CD, those with 
colonic involvement alone had the highest incidence of peripheral arthritis. In patients of 
UC, total colectomy may prevent further attacks of  peripheral arthritis and such surgery 
does not typically prevent recurrent arthritis in CD. The possible pathogenesis being that 
the diseased bowel may provide the immunological stimulus for the occurrence of 
arthritis. In the case of UC, total colectomy provides removal of all diseased bowel and 
thereby removal of arthritogenic stimulus. In CD surgical removal of the entire diseased 
bowel is unusual.  (Gravallese et al) 
The peripheral arthropathy associated with either UC or CD involving the colon is 
more commonly observed during an exacerbation of bowel symptoms, is common in 
patients with chronic inflammatory bowel disease than in individuals with an acute 
fulminant colitis and is more likely seen in patients with universal or left sided colitis 
than in those with inflammation limited to rectosigmoid area. The incidence of either the 
peripheral arthropathy or ankylosing spondylitis is not increased by the presence of 
intestinal complications such as fistula or stricture with either UC or CD. (Thomas Danzi 
et al) 
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Evidence of Gut-Joint Enteropathy in axial involvement 
Two forms of axial involvement are noted in IBD. The first is spondylitis which includes 
sacroiliitis and is indistinguishable clinically and radiologically from idiopathic 
ankylosing spondylitis. The second is an isolated sacroiliitis which is often 
asymptomatic. (Gravallese et al). The degree of peripheral joint involvement appears to 
correlate with the degree of bowel inflammation whereas the spondyloartropathies tend to 
progress without relation to the intestinal disease. (Norton et al) 
Axial involvement in IBD can vary from asymptomatic sacroiliitis to classic 
ankylosing spondylitis. Radiographic involvement of sacroiliitis of at least grade II was 
noted in 11% of CD patients. The prevalence varies from 3% to 10%. There are some 
observations which suggest alterations in gut flora especially the presence of Klebsiella in 
the gut but the presence of bacterial agents in axial joints has generally not been detected 
low due to low joint accessibility.The contrary is also true with the presence of gut 
alterations in about 60% of spondyloarthropathy patients varying from increased 
lymphoid follicles to chronic intestinal inflammation. (De Vos et al) 
Although there is no increased incidence of HLA B27 in enteropathic peripheral 
arthritis, there is reportedly an increased incidence of HLA B27, 53% - 75% in patients 
with spondylitis and IBD. Relatives of patients with IBD have higher spinal inflammation 
though the probands have no evidence of spinal involvement suggesting a genetic 
predisposition. (Gravallese et al) 
De Vos et al demonstrated a gradient increase in the prevalence of HLA B27 from 
0% in CD with inflammatory back pain only to over 14% in patients with isolated 
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sacroiliitis and upto 78% in patients with ankylosing spondylitis suggesting that evolution 
to ankylosing spondylitis is more likely in HLA B27 positive patients. (De Vos et al) 
 
Proposed etiopathogenesis mechanisms in gut joint involvement 
A number of bacterial agents such as Gram negative invasive E. coli and Gram negative 
anaerobic rods of Bacteroides and Fusobacterium are implicated in the etiopathogenesis 
of CD. Similar bacterial agents are involved in the etiopathogenesis of 
spondyloarthropathy. 
Intestinal bacteria may reach the dendritic cells and macrophages in different 
ways - transport by M cells; uptake and processing by epithelial cells; direct access to 
dendrites located between epithelial cells and direct access to antigen presenting cells 
through the breaks in the epithelial barrier. 
Polymorphisms of CARD 15 are associated with CD and also it has role in 
bacterial handling. CARD 15 is located on the chromosome 16 and encodes for an 
intracellular protein with binding affinity to bacterial muramyl peptide. CARD 15 protein 
is expressed by monocytes, macrophages and dendritic cells. In vitro it induces the 
activation of nuclear factor κB pathway after recognition of muramyl peptide. It helps in 
protecting the gut wall against aggression. Genetic modulation of CARD 15 expression 
may lead to disturbed handling of bacterial products/inappropriate elimination.  
T cells in the lamina propria of CD and spondyloarthropathy patients produce 
interferon γ resulting in production of proinflammatory cytokines (tumour necrosis factor 
α, interleukin 6 and interleukin 1). Effector T cells migrate from inductive sites to 
adhesive sites and the expression of the adhesion molecules regulate the cell traffic. 
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Intestinally activated T cells may enter the synovium either by the presence of cognate 
antigens at both sites or by homing of lymphocytes primed in gut by α4β7 and vascular 
adhesion protein 1 (VAP1). The discovery of identical T cell expansions in colonic 
mucosa, synovium and blood support this concept of gut – joint iteropathy. (Ekkehard et 
al)  
There are numerous case reports in the literature describing IBD with persistent erosive 
monoarthritis. Pathological examination of the synovial tissue revealed chronic synovitis 
with single or multiple noncaseating epitheloid granulomas. The granulomas were similar 
to those noted in involved bowel wall. (Gravallese et al) 
 
Enteropathic arthritis 
The clinical characteristics of arthritic flares are similar in both UC and CD. Palumbo et 
al reviewed the articular manifestations of 121 patients with IBD and found no 
distinguishing characteristics between the arthritis that is seen in CD and that seen in UC. 
Joints most commonly involved in arthritic flares are knees, ankles, elbows and wrists 
followed by proximal interphalangeal joints, metacarpophalangeal joints and 
metatarsophalangeal joints. Knees and ankles are the joints that are most commonly 
involved in first attacks. Hips and shoulders are less commonly involved in patients 
without associated spondylitis. The onset of arthritis may be insidious. Over 90% of 
attacks are polyarticular and a migratory pattern of joint involvement is noted in 50% of 
the patients. In fifty percent of the patients the duration of arthritic symptoms lasted less 
than 1 month; 25% of attacks lasted 5 weeks to 2 months; 10% of attacks lasted 2-6 
months and 10% lasted 6-12 months. In the remaining 5% of the cases a chronic arthritis 
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lasting for several years ensued.  The peripheral arthritis associated with IBD is of non-
deforming and non destructive type. Although pain and limitation of joint motion and 
joint effusion are common clinical findings at flares these often resolve without sequelae.  
(Gravallese et al) 
Orchard et al analysed the natural history and articular distribution of peripheral 
joint involvement without axial disease in a cohort of IBD patients. They described 2 
forms of peripheral arthropathy. Type 1 (pauciarticular) characterised by self limiting 
attacks of oligoarthritis (less than 5 joints) that often coincided with relapses of IBD. 
Type 1 occurred in 4.4% of the patients and was associated with HLA B 27 in 26% of the 
patients. Type 2 (polyarticular) was noted to involve more than 5 joints, occurred in 2.9% 
of IBD patients, with a more severe course of symptoms persisting for months to years 
independent of the IBD activity. (Orchard et al) Salvarani et al in a population based 
study of 202 IBD patients did not observe any association between peripheral arthritis of 
IBD and HLA B 27 antigen. (Salvarani et al) 
The clinical features of spondylitis associated with IBD are similar to those seen 
in idiopathic ankylosing spondylitis. The low back pain is insidious in onset with 
morning stiffness. Pain is usually better after exercise and worse with rest. Physical 
examination reveals limited spinal flexion and reduced chest expansion. Spondylitis in 
IBD can occur at any age. In contrast to the peripheral arthritis associated with IBD, 
symptoms of spondylitis tend to be unrelated to the exacerbations and remissions of 
bowel disease. Axial symptoms usually occur after onset of bowel symptoms but may 
precede the bowel symptoms. Distinct from the enteropathic peripheral arthritis is an 
arthritis involving large joints seen specifically in patients with spondylitis. The hips and 
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shoulders are specifically involved and to a lesser extent the knees. Hips and shoulders 
may be permanently damaged.  (Gravallese et al) 
 
Classification of enteropathic peripheral arthropathy (Orchard et al) 
Type 1 (pauciarticular) 
+ Less than 5 joints 
+ Acute, self-limiting attacks (<10 weeks) 
+ Often coincides with relapses of IBD 
+ Strongly associated with extraintestinal manifestations of IBD 
Type 2 (polyarticular) 
+ Five or more joints 
+ Symptoms usually persist for months to years 
+ Runs a course independent of IBD 
+ Associated with uveitis but not with other extraintestinal manifestations 
 
Relevant gut biology: 
The adult human gastrointestinal tract is not a complete barrier, being permeable to some 
macromolecules. Permeability is increased in certain disease states, including 
inflammatory bowel disease, celiac disease, and the administration of nonsteroidal 
antiinflammatory drugs.Thus, the adult gastrointestinal tract is a potential source for 
exposure to both bacterial and dietary antigens, particularly when permeability is 
increased (Bjarnason,et al., Smth et al.,).  
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The human gastrointestinal tract plays host to a large number of bacteria, 
consisting of more than 400 species, their total number exceeding the number of cells in 
the human body. The large majority of these bacteria are anaerobic. These bacteria play 
an important role in human health by producing nutrients, preventing colonization of the 
gut by potential pathogens, and affecting immune responses (Guarner et al; Ramakrishna 
et al)    The healthy gut harbors a mixture of native bacteria acquired at birth or shortly 
thereafter that retains a relatively constant composition; it also has a smaller population 
of transient bacteria of varying composition. The former are essential for health and live 
in symbiosis; the latter contain potential pathogens. Whereas the stomach and duodenum 
normally contain less than 103 mucosa-adhering bacteria, the number of bacteria 
increases to 104 in the jejunum and 107 in the ileum. Most of this last group is gram-
negative aerobic species. In the colon, the bacterial density is 1012 or more, consisting 
mostly of anaerobic bacteria. Transit time is fast in the upper gut and slow in the distal 
gut, but the immunologic impact of the microflora is higher in the proximal parts of the 
gut. (Guarner et al) 
Antigenic exposure via the gastrointestinal tract usually results in tolerance rather 
than immunity. Normal individuals appear to be tolerant to their own intestinal flora, but 
intolerant to that of others. Patients with active IBD lose tolerance to their own bacterial 
flora, an abnormality that is reversed when the disease comes under control. Whether this 
loss of tolerance is a cause or a consequence of the IBD is not known (Duchmann et al.,) 
Enhanced mucosal permeability may play a pivotal role in maintaining a chronic 
inflammatory state, due to a genetic predisposition or as a result of direct contact with 
bacteria or their products . A defective epithelial barrier may cause a loss of tolerance to 
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the normal enteric flora. Furthermore, an increased mucosal absorption of viable bacteria 
and bacterial products is found in IBD. Serum and secreted antibodies are increased and 
mucosal T-lymphocytes that recognize luminal bacteria are present. However, there is 
evidence that the immune system reacts over aggressively towards the normal luminal 
flora rather than the flora being altered in IBD. Several approaches have been used in 
attempts to discover a specific microbial agent in the cause of IBD. These include 
demonstration of the presence of organisms or specific antigens in affected tissues, 
culture of microbes from the affected tissues, demonstration of serological responses to 
several agents, and localization and detection of individual pathogen-specific nucleic acid 
sequences in affected tissue by in situ hybridization and polymerase chain reaction. So 
far, no specific micro-organism has been directly associated with the pathogenesis of 
IBD. Analysis of the luminal enteric flora, however, has revealed differences in the 
composition of this flora compared to healthy controls . In Crohn disease, concentration s 
of Bacteroides, Eubacteria and Peptostreptococcus are increased, whereas Bfi dobacteria 
numbers are significantly reduced. Furthermore, in ulcerative colitis, concentrations of 
facultative anaerobic bacteria are increased.(Linskens RK et al) 
Gut associated lymphoid tissue 
Gut-associated lymphoid tissue (GALT) is the largest lymphoid organ of the body, 
constituting 25% of the mucosal mass. The gastrointestinal tract has been called “the 
most misunderstood and underappreciated lymphoid organ of the body”. GALT 
components are found in Peyer's patches, gut lymphoid follicles, lamina propria, and 
intraepithelial T cells. From the Peyer's patches, primed B lymphocytes disseminate 
throughout the body's mucous membranes, notably to other parts of the alimentary tract. 
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Primed T lymphocytes also disseminate into the circulation and lymph nodes and home 
into target organs, such as salivary glands (in Sjögren's disease), lungs, and synovium. A 
chain of events in the pathogenesis of enteropathic arthritis can begin with 
gastrointestinal infection with the appropriate microorganism in a genetically predisposed 
patient. This causes local inflammation in the gut mucosa, formation of secretory IgA, 
increased permeability, absorption of foreign material, and triggering of T lymphocytes. 
Circulating immune complexes and memory T cells localize to joints and cause synovitis. 
(Fumiko  et al)  
The pathogenesis of ulcerative colitis (UC) remains unclear. The disease is 
characterized by exacerbations and remissions and runs a prolonged course. In addition to 
possible genetic factors concerned with immunoregulation and altered mucosal barrier 
function, dysbiosis which is an abnormal ratio of beneficial to detrimental commensal 
microbial agents has also been implicated in disease pathogenesis and relapse (Balfour et 
al) The normal resident intestinal flora prevents the overgrowth of pathogenic bacteria. 
Clostridium difficile is a Gram-positive anaerobic bacterium that is present as a very 
minor constituent of the colonic flora. The use of broad spectrum antibiotics disrupts the 
ecosystem of the normal colonic flora, and may predispose to colonization of harmful 
bacteria. (Balamurugan et al) 
The bacterial answer to CD and ulcerative colitis (UC) could be revealed in the 
difference in the colonic flora between identical twins discordant for the disease. The 
twin data also suggest the organism needs to be present in 80% of people (60 +60 + 40 = 
80% of 200 individuals in 100 sets of identical twins). Antibodies to Enterococcus 
faecalis and E. coli have been found with increased frequency in affected bowel mucosa 
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of patients with CD. The ubiquitous presence of E. coli in the stool would not fit the 
discordant twin data; however, the 80% prevalence of enterococcus would. The immune 
handling of enterococcus is important in understanding the pathogenesis of IBD. (Joseph 
McKinley et al). 
 
Joint manifestations of UC: 
Frequency of peripheral arthritis in UC: 
The reported prevalence of peripheral arthritis in UC varied from 0.9% to 34.6% in 
various studies. Out of 28 surveys, 19 studies concluded with a frequency of arthritis of 
less than 11%. However most of the studies were on hospitalized patients in whom there 
will be tendency of more association between the two disorders. Arthritis in UC was 
noted to be more prevalent in women than among men. In the majority of cases, colitis 
preceded the development of arthritis whereas in 0-25% of cases, the onset of arthritis 
antedated that of UC. A simultaneous occurrence of joint disease and UC was seen in no 
more than about 20% of cases. In a study by Mc Ewan et al., simultaneous flares of 
colitis and peripheral arthritis were observed in 60% of the patients. Arthritis tends to 
wax and wane with the activity of bowel disease and not every relapse of colitis will be 
followed by joint disease. In a survey by Wright and Watkinson, if rectum alone was 
affected only 4.9% had arthritis which sharply contrasted with the 14.4% incidence of 
arthritis among patients whose entire colon was affected. The joint distribution is most 
often asymmetric but symmetric is also common most frequently noted in the lower 
limbs. An attack of arthritis involves from 1-3 joints and less than 10% of cases have 
more than 6 joints involved. In 1952, Dennis and Karlson, showed that out of 19 patients 
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with UC and arthritis, all but 1 improved following removal of the colon and enjoyed 
complete loss of symptoms (Jan tore gran et al). 
Frequency of Ankylosing Spondylitis (AS) and sacroiliitis in UC: 
The first author to report the association between AS and UC was Romanus in 1953. 
Reported prevalence of AS in UC varies between 0.8 and 6.0%. Many studies concluded 
with the prevalence ranging between 3 and 6%. There is discrepancy regarding the date 
of onset of both the disorders. The clinical picture of AS develops without any consistent 
time or disease activity of UC and the relationship is based upon the disease susceptibility 
genes for one condition predisposing the other. Wright and Watkinson reported that 
sacroiliitis was observed in 13% of patients with rectal involvement as compared to 
23.2% in whom the entire colon is affected. The radiological finding of sacroiliitis was 
noted to be a rather frequent feature of UC (18%) in contrast to AS which occurred in 
3.3% of the cases. The prevalence of UC in AS was about 20 times higher than the 
general population.  (Jan tore gran et al). 
Joint manifestations of CD: 
Frequency of peripheral arthritis in CD: 
The prevalence of peripheral arthritis in CD varies from 0.4 to 23.0%. The peripheral 
arthritis of CD resembles that of UC. The joints most commonly involved are the knees 
and the ankles. Destruction of joints is rarely encountered. In the majority of patients the 
arthritis follows the bowel involvement. CD without colonic involvement has a reduced 
incidence of peripheral arthritis may support the notion that the distal part of the bowel 
plays a critical role in the development of joint manifestations. The beneficial effects of 
surgery upon arthritis are less pronounced in CD than in UC. According to other workers 
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the exacerbation of joint symptoms in CD subsequent to resection invariably heralds a 
recurrence of the intestinal lesion (Jan tore gran et al). 
Frequency of Ankylosing Spondylitis (AS) and sacroiliitis in CD: 
The prevalence of ankylosing spondylitis in CD varies between 2.0 % and 9.8% with 
most surveys estimating the prevalence between 2 and 4%. The clinical picture is similar 
to that in UC. The prevalence of CD in ankylosing spondylitis seems to be 40 – 50 times 
higher than that in general population (Jan tore gran et al). 
.  
Role of HLA B27:  
The remarkably strong association of spondyloarthropathies (SpA) with the major 
histocompatibility complex (MHC) class I gene human leukocyte antigen (HLA)-B27 
was first described in 1973. The HLA-B27 transgenic rat model represents a unique 
model to understand the role of the HLA-B27 gene in SpA with associated inflammatory 
bowel disease (IBD). The inflammatory cytokine pattern of HLAB27 transgenic rats (T 
helper [Th]1>Th2 cytokine expression) corresponds to that observed in Crohn’s disease, 
while the  histological features of their colitis closely resemble those of ulcerative colitis. 
Usually, IBD and arthritis symptoms do not develop under germ-free state but under 
pathogen conditions. In HLA-B27 transgenic rats, colitis is the earliest clinical 
manifestation, with diarrhea appearing after 10 weeks of age, while after several weeks of 
the onset of intestinal inflammation most affected rats develop peripheral arthritis. Recent 
evidence indicates that, in HLA-B27 transgenic rats, the presence of both CD4+ 
T cells and antigen-presenting cells (APCs) expressing high levels of HLA-B27 seems to 
be of critical importance in the pathogenesis of the disease. Because of the lack of a 
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demonstrable role of CD8+ T cells, recent hypotheses to explain the pathogenecity of 
HLA-B27 in this model are based on non-antigen-specific mechanisms, as opposed to the 
classic arthritogenic peptide-based hypotheses.  This antigen-independent defect has been 
examined primarily in DCs and occurs at the level of contact between APCs and T cells. 
In these rats, APCs have relatively poor efficacy in stimulating T cells, and this could 
result in loss of tolerance toward self-antigens. Alternatively (or additionally), impaired T 
cell stimulation could result in altered control of gut bacteria, thereby sustaining 
stimulation of immune defense by macrophages. Therefore, IBD as well as arthritis 
symptoms can be prevented in “germ-free” conditions, while bacterial flora reconstitution 
fosters disease development (Anna Farca et al). 
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Fig; 1: Etiopathogenesis of Enteropathic arthritis 
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Treatment of enteropathic arthritis: 
Therapy for rheumatological complications is secondary to treatment of the underlying 
IBD and generally directed towards reducing joint inflammation and preventing disability 
and deformity (especially axial symptoms).Guided physical therapy is of great 
importance in patients with axial arthropathy. Primary goals of physical therapy are to 
relieve pain, to secure optimal mobility and posture, to retard progressive clinical 
complaints and to reduce the consequences of spinal joint fusion. Sulphasalazine is the 
active moiety against both bowel and arthritic inflammation and should be considered a 
first line medical therapy. Non steroidal anti-inflammatory drugs (NSAIDS) are used 
frequently in arthritis but they may activate IBD. Intra articular steroids can have an 
effect that will last for months. Oral steroids are very effective. Azathioprine and 
methotrexate are appropriate for maintenance therapy. Recalcitrant disease may 
necessitate use of infliximab/ etanercept. ( Daniel et al) 
Summary of review of literature: 
The diagnosis of enteropahic arthritis is made in a patient with IBD by the presence of 
asymmetrical, often migratory, non erosive and seronegative often migratory arthritis 
occurring most often in knee and ankle noted in 15- 20% of IBD more commonly in CD 
than in UC. As the arthritic flares accompany flares of underlying intestinal disease 
suggests a cause and effect relationship. An immunologic reaction to gut bacteria has 
been postulated in IBD. The therapy is usually directed at intestinal disorder and the 
peripheral arthritis tends to be corticosteroid responsive. It is not clear whether it is a true 
synovial response or steroids causing quiescence of bowel disease and thereby decreases 
in the immunologic stimulus for the ongoing arthritis.  
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Spondylitis occurs in 3-6% of patients with IBD with similar incidence in CD and UC. 
However radiological evidence of sacroilitis is reported more frequently (14-20%). The 
clinical course of axial arthropathy is unrelated to bowel disease activity and has an 
association with HLA B 27 which was distinct with that of the enteropathic peripheral 
arthritis. Cases in which spondylitis clearly precedes the onset of bowel disease argue 
against the cause and effect relationship.  
 
 
 
 
Fig 2: Proposed model of immunopathogenesis of ulcerative colitis and its 
extraintestinal manifestations 
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The model is based upon the unique distribution of a "shared autoantigen(s)" in the four 
extracolonic organs, namely eye, skin, biliary epithelium and joints. Because 
autoantibodies against human tropomyosin (hTM) isoform 5 and colon epithelial specific 
protein (CEP) have been demonstrated in UC and not in CD and other non-IBD controls, 
it is possible that both proteins, either individually or as an hTM+CEP complex, act as 
autoantigen(s) or are involved in the pathogenesis of UC. The autoantibodies belong to 
IgG1 subclass and can activate the complement system causing deposition of C3 and 
products of terminal complement complex (TCC) on the colonocytes in UC. 
Autoantigen-specific B cells can also act as APC, maintaining perpetuation of 
inflammatory process. Microbial peptide(s) crossreactive to the cellular autoantigenic 
epitope(s) (molecular mimicry), or release of cryptic peptide by local factors such as 
trauma, may initiate the autoimmune response. CEP/hTM5 associated epitope(s) are 
expressed at the selective extracolonic sites such as, non-pigmented ciliary epithelium in 
the eye, keratinocytes, biliary epithelium and chondrocytes. ( Das et al.,) 
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PARTICIPANTS AND METHODS 
 
 
A total of 128 consecutive patients with inflammatory bowel disease, seen between 
January 2007 and March 2009 at CMC, Vellore, were included in the study. Clinical 
information, laboratory and treatment data were collected for all patients by using uniform 
structured data forms (Proforma). 
 
 Participants: 
Inclusion Criteria 
All patients diagnosed to have IBD (ulcerative colitis or Crohn’s disease) either newly or 
in the past and who were seen in the IBD or GE clinics. 
Exclusion criteria 
1. Failure to provide consent 
2. Patients with intestinal tuberculosis, indeterminate colitis or uncharacterized bowel 
disorder. 
3. Antibiotic therapy within the past month. 
 
Diagnosis of ulcerative colitis was based on the following criteria (Ouyang et al.,) 
1. History of diarrhea or rectal bleeding for 6 weeks or more and  
2. Colonoscopy and histology showing features suggestive of ulcerative colitis  
The extent of the disease was assessed by colonoscopy and biopsy and was classified as 
proctosigmoiditis (involvement of rectum and sigmoid colon), left sided colitis 
(involvement upto splenic flexure) and pancolitis (disease proximal to splenic flexure).  
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Diagnosis of Crohn’s disease was based on the presence of following features in varying 
combination (APDW 2004) 
1. Colonoscopy: Skip areas, cobblestone appearance, linear or serpiginous ulcer, 
fistula  
2. Histopathology: Crypt architecture abnormalities, mononuclear infiltration, 
granulomas, transmural inflammation, segmental distribution of the lesion, patchy 
and focal inflammation. 
3. Radiology: Skip lesions, fistula ( entero-enteric or enterocutaneous), cobblestone 
appearance, combination of linear ulcer, deep transverse cleft, asymmetric 
involvement, creeping fat. 
4. Response to therapy 
Methods: 
All patients included in the study were formally interviewed by the principal investigator 
who also performed a complete clinical examination. The nature of the disease was 
explained and investigations were then advised. These included upper and lower 
gastrointestinal endoscopy with segmental biopsies which is part of the current standard 
of care in this institution, and all investigations were done only as clinically indicated. 
Disease severity of CD was assessed using Harvey Bradshaw score (<4, mild; 5–8, 
moderate; >9, severe) and of UC using Montreal disease activity index [ S0- Clinical 
Remission (asymptomatic); S1- Mild UC {passage of 4/fewer stools /day (with or 
without blood), absence of any systemic illness and normal inflammatory markers 
(ESR)}; S2- Moderate UC (more than 4 stools per day but with minimal signs of 
systemic toxicity) ; S3- Severe UC (at least 6 bloody stools daily, pulse rate of at least 90 
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beats/min, temperature of at least 37.5C, Hb <10.5g/100mL and ESR of at least 
30mm/hr)]. Clinical details and laboratory results were all entered into structured forms 
and retained separately from the case records. The response to therapy and follow up 
were also recorded.  
The presence of joint symptoms was noted. The pattern of joint involvement was 
noted and functional index was graded. The joint findings were cross-checked by a 
specialist rheumatologist. Radiographs of the involved joints were done for deformities. 
X rays of sacroiliac joint (antero posterior view) and spine were obtained and sacroiliac 
joint changes were graded according to New York criteria (calin et al.,). 
Patients were also asked to provide a sample of stool to the laboratory for 
quantitative molecular characterization of specific classes of the bacterial flora - 
Bacteroides, Eubacterium, Clostridium, bifidobacteria, and lactobacilli. These bacterial 
groups were chosen for the following reasons. Bacteroides is generally believed to be 
aggressive in stimulating the innate immune system, while Bifidobacteria and 
Lactobacilli are both used as probiotics to ameliorate inflammation. Specific alterations 
in Eubacterium and certain classes of Clostridia are known to occur in inflammatory 
bowel disease. A separate control group was not included in the study because the 
intention was to compare the bacterial flora of patients with arthritis and the flora of 
patients without arthritis.  
Written informed consent to enter the study was obtained from all participants. 
The protocol and consent form were approved by the Institutional Review Board 
comprising the scientific and ethical research committee. 
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Sample size calculation 
This was a cross-sectional study of a population of individuals with inflammatory bowel 
disease. The sample size considerations were therefore as follows, and are different from 
sample sizes from a conventional case-control study. We assumed that 15% of the IBD 
patients would have joint disease. This study was powered on the basis of finding 
quantitative differences in the fecal bacterial flora. Utilising mean and standard deviation 
data from our previous studies of the fecal bacterial flora (Balamurugan et al. Journal of 
Gastroenterology & Hepatology 2008) we calculated that a sample size of 138 patients 
(i.e. 18 patients with joint symptoms and 120 without) would provide 80% study power 
to be able to discriminate patients with a two-fold change in specific bacterial population. 
In this context, it must be noted that traditional quantitative intestinal microbiology 
considered ten-fold difference in bacterial population as biologically significant, and 
therefore the ability to discriminate two-fold difference was more than sufficient for our 
purposes.   
Statistical analysis: 
Comparison between the UC and the CD group as well as the joint and the non-joint 
groups was done by Fischer’s exact test for categorical variables and Mann-Whitney U 
test for continuous variables. IBD patients with joint features were treated as “cases” and 
IBD patients without the joint features were treated as the controls for the purpose of data 
analysis. For continuous data with normal distribution mean and standard deviation is 
reported.  For continuous data without normal distribution the median and range is 
reported.  A two tailed p value of ≤ 0.05 was considered significant. Mean and standard 
deviation were calculated. All analysis was performed in SPSS for Windows Version 11. 
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DNA Extraction and PCR:  
Sample collection and processing 
Subjects were provided with stool collection kits that included a stool box, tissue, napkins 
and a wooden spatula. Fecal specimens were collected in sterile containers. Immediately 
after receipt in the laboratory, samples were stored at –80ºC. 
DNA EXTRACTION AND PURIFICATION 
Principle: The QIAamp DNA Stool Mini Kit provides fast and easy purification of 
total DNA from fresh or frozen stool samples. QIAamp purified DNA is ideal for 
reliable use in PCR and other downstream enzymatic reactions. The QIAamp DNA 
Stool Mini Kit is designed for rapid purification of total DNA from up to 220 mg of 
stool and is suitable for both fresh and frozen samples. A special protocol is provided 
for isolating DNA from larger amounts of stool. The procedure comprises the 
following steps: 
¾ Lysis of stool samples in Buffer ASL. 
¾ Adsorption of impurities to InhibitEX. 
¾ Purification of DNA on QIAamp spin columns. 
Procedure: 
1. Weigh 180–220 mg stool in 2 ml microcentrifuge tube and place tube on ice. 
2. Add 1.4 ml Buffer ASL to each stool sample. Vortex continuously for 1 min 
or until the stool sample is thoroughly homogenized. 
3. Heat the suspension for 5 min at 95°C. 
4. Vortex for 15 s and centrifuge sample at full speed for 1 min to pellet stool 
particles. 
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5. Pipette 1.2 ml of the supernatant into a new 2 ml microcentrifuge tube (not 
provided) and discard the pellet. 
6. Add 1 InhibitEX tablet to each sample and vortex immediately and 
continuously for 1 min or until the tablet is completely suspended. Incubate 
suspension for 1 min at room temperature to allow inhibitors to adsorb to the 
InhibitEX matrix. 
7. Centrifuge sample at full speed for 3 min to pellet inhibitors bound to 
InhibitEX. 
8. Pipette all the supernatant into a new 1.5 ml microcentrifuge tube (not 
provided) and discard the pellet. Centrifuge the sample at full speed for 3 min. 
9. Transfer of small quantities of pellet material from step 7 will not affect the 
procedure. 
10. Pipette 15 μl Proteinase K into a new 1.5 ml microcentrifuge tube. 
11. Pipette 200 μl supernatant from step 8 into the 1.5 ml microcentrifuge tube 
containing Proteinase K. 
12. Add 200 μl Buffer AL and vortex for 15 s. 
13. Incubate at 70°C for 10 min. 
14. Add 200 μl of ethanol (96–100%) to the lysate, and mix by vortexing. 
Optional: Centrifuge briefly to remove drops from the inside of the tube lid. 
15. Label the lid of a new QIAamp spin column placed in a 2 ml collection tube. 
16. Carefully apply the complete lysate from step 13 to the QIAamp spin column 
without moistening the rim. Close the cap and centrifuge at full speed for 1 
min. 
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17. Place the QIAamp spin column in a new 2 ml collection tube, and discard the 
tube containing the filtrate. 
18. Carefully open the QIAamp spin column and add 500 μl Buffer AW1. 
Centrifuge at full speed for 1 min. Place the QIAamp spin column in a new 2 
ml collection tube, and discard the collection tube containing the filtrate. 
19. Carefully open the QIAamp spin column and add 500 μl Buffer AW2. 
Centrifuge at full speed for 3 min. Discard the collection tube containing the 
filtrate. 
20. Transfer the QIAamp spin column into a new, labeled 1.5 ml microcentrifuge 
tube (not provided) and pipette 200 μl Buffer AE directly onto the QIAamp 
membrane. 
21. Incubate for 1 min at room temperature, then centrifuge at full speed for 1 min 
to elute DNA. 
22. DNA yield is determined by measuring the concentration of DNA in the 
eluate by its absorbance at 260 nm. Absorbance readings at 260 nm (A260) 
should fall between 0.15 and 1.0 to be accurate. 
Quantitative PCR 
The molecular methods and protocols used for fecal bacterial quantitation have been 
standardized for this laboratory and published earlier (Balamurugan et al, JPGN 2008, 
JGH 2008, AJCN 2009). Real-time PCR primers were designed for bacterial species 
/groups, representing fecal microbes. The Ribosomal Database Project (Maidak et 
al.,2001; http://rdp.cme.msu.edu/html/) was utilized for identifying the primers that were 
likely to bind with the desired specificity to the rDNA of the selected target bacteria. The 
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PCR primers against Bacteroides-Prevotella-Porphyromonas Bifidobacterium genus  
Lactobacillus, Desulfovibrio specific primer and Eubacterium rectale-Clostridium 
coccoides cluster were designed on the basis of 16S rRNA gene sequences, available at 
the National Center for Biotechnology Information databases. A wide range of bacterial 
species was tested to confirm the specificity of the developed primers to target bacteria 
using conventional PCR. The Bifidobacterium genus detected all Bifidobacterium 
species, Lactobacillus acidophilus group primers detected L. acidophilus, L. 
amylovorus, L. amylolyticus, L. crispatus, L. gasseri and L. johnsonii. The other 
genus or group-specific primers detected all bacteria in that genus or cluster. 
Primers were also used to amplify a conserved 16S rDNA sequence present in all 
bacteria, the universal primer set. 
The PCR amplification and optimal annealing temperatures of the PCR primers 
were initially optimized with gradient PCR in a Chromo 4 system (MJ Research/Biorad, 
USA) using SYBR Green master mix (Eurogentec, Belgium). All PCRs were performed 
in duplicate in a volume of 20μl, using high profile tubes and ultraclear sealing caps (MJ 
Research/Biorad, USA). The amplified products after a gradient PCR were subjected to 
electrophoresis and checked for the single, expected band and also were compared with 
the melting curve analysis. The following optimized PCR conditions were used for the 
real-time PCR. Reaction mixtures had 2X SYBR green master mix (200μM each dNTPs, 
5mM MgCl2), 0.5μM each primer, 2μl of template and water was used to make up to the 
final volume. The thermal cycling conditions started with an initial activation step at 
50°C for 2 min and an initial denaturation step at 95°C for 10 min, which was followed 
by 45 cycles of denaturation at 95°C for 15 sec, annealing at 61°C for 30 sec, extension at 
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72°C for 30 sec and a plate read step. The final extension step at 72°C for 10 min was 
followed by a melting curve analysis, which was performed by increasing the 
temperature from 40°C to 95°C, with a raise in temperature by 1°C every 10 sec with a 
plate read step to read the fluorescent signal. 
For quantitation of the number of bacterial for each target bacterial groups present 
in each sample, fluorescent signals detected from each sample and compared to a 
standard curve generated with standard DNA in the same experiment. Quantitation was 
analyzed by the Opticon 3.1 software provided with the Chromo 4 real-time PCR. 
Bacterial quantitation data were expressed as log10 CFU/g stool. 
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                                                            RESULTS 
A total of 128 patients could be recruited for the study during this period. Of the 128 
patients with IBD, 60 patients had a diagnosis of CD (mean + SD age: 38.2 + 15.3yr; 
range from 12 yr to 70 yr) and 68 patients had UC (mean + SD age: 37.5 + 14.6 yr; range 
from 2 yr to 78 yr). There were more men patients – UC (M:F = 38:30)  and in CD (M:F 
= 40:20). Majority of the patients belonged to eastern (n=66) and southern (n=48) parts of 
India. The mean duration of delay in diagnosis was 66 + 79.4 months. 
 
Table : 1 Clinical manifestations of patients with inflammatory bowel disease: 
 
Cl Features CD n =60 (47%) UC n=68 (53%) IBD n = 128 (100%) 
Age, Yr 38.22 +15.3 37.53 + 14.6 37.8 + 14.8 
Sex M:F 40:20 38:30 78:50 
Abdominal pain 49 (82%) 46 (67.6%) 95 (74.2%) 
Diarrhoea* 33 (55%) 68 (100 %) 101 (79%) 
Blood in stools* 28 (46.7%) 66 (97.1%) 94 (73.4%) 
Fever* 22 (36.7%) 8 (11.8%) 30 (23.4%) 
Intestinal Obstruction* 29 (48.3%) 2 (2.9%) 31 (24.2%) 
Weight loss 
< 5 Kg:5-10: >10Kg wt loss 
Rest no weight loss 
16:22:7 
26.7%:36.7%:11.7%
32:12:4 
47.1%:17.6%:5.9% 
48:34:11 
37.5%:26.6%:8.6% 
Perianal features 
Fissure: Abscess: Fistula: 
Ulcer 
5:1:6:1 6:1:3:0 11:2:9:1 
Past h/o appendicectomy*             6 (10%)                 0                  6 
Arthritis no. (%)          13 (21.6)           11 (16.1)            24 (18.7) 
Values shown are mean + SD or number (percentage). * p < 0.05 
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Table 2: Laboratory parameters in the study population  
 
 CD 60 UC 68 
Hb [mean(SD)]; range 10.7 (2.4); 2.7 – 15.5 11(2.6) 4.5 – 16.9 
MCV (mean) 76.2 77.2 
ESR [mean(SD)]; range 37.8 (31.3);2-135 39.1 (29) 
CRP [mean(SD)] 18.3 (35.1) 24.9 (38.2) 
S. Albumin [mean(SD)]; 
range 
3.9 (0.8); 2-5 3.5 (1) 
SAP [mean(SD)] 80 (57) 92.2 (46.6) 
UGI : 
Not Done 
Normal 
Others 
 
Granuloma 
 
14 
40 
Ulcer/erosion/nodule: 6 
 
3 (5%) 
 
38 
27 
Antral granularity/ attenuated D2 
folds: 3 
0 
LGI: 
Not Done 
Findings: 
 
 
 
 
 
Granulomas 
 
9 
Ileal ulcer/ nodularity:17 
Skip lesions: 13 
Deformed IC valve: 2 
Fistula: 1 
Diffuse ulceration: 2 
Normal : 20 
8 
 
0 
Proctitis: 16 (23.5%) 
 
Proctosigmoiditis: 20 (29.4%) 
 
Pancolitis: 32 (47.1%) 
 
0 
Radiology: 
BMFT 
CECT: 
USG Abdomen: 
Not Done 
 
Possible CD: 8; Normal: 5 
Possible CD:18; Normal:4 
Possible CD: 1; Normal:3 
21 
 
Normal: 11; UC:2 
Normal: 1; UC: 3 
Normal: 5; UC:2 
44 
Behaviour Stricturing: 31 (51.7%) 
Non structuring – non 
fistulizing: 26 (43.3%) 
Fistulizing: 2 (3.3%) 
Stricturing & fistulizing: 1 
(1.7%) 
 
Location Colonic 11 (18.3%) 
Ileal 29 (48.4%) 
Ileocolonic 18 (30%) 
UGI 2 (3.3%) 
Procto - Sigmoiditis : 16 (23.5%) 
Left sided colitis: 20 (29.4%) 
Pancolitis: 32 (47.1%) 
Severity <4: Mild: 24 (40%) 
5-8: Moderate: 22(36.7%) 
>9: Severe: 14 (23.3%) 
S0 :1 (1.5%) 
S1: 14 (20.6%) 
S2: 27 (39.7%) 
S3: 26 (38.2%) 
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Crohn’s disease: 
The mean age of patients with CD was 38.2 + 15.3 years with majority being male 
patients (67%). Abdominal pain was the commonest symptom followed by tiredness and 
diarrhoea. Extra intestinal features were present in 14 patients – joint symptoms in 13 
(with a patient having episcleritis) and a patient with scleritis alone.  Ileal disease was the 
commonest type followed by ileocolonic and colonic disease.  Disease severity at 
diagnosis assessed using the Harvey Bradshaw score showed the majority (59%) of 
patients had moderate to severe disease.  
All patients were treated with 5-ASA preparations, the type of preparation (5 – amino 
salicylate, Sulfasalazine) chosen depending on site of disease. Remission induction using 
oral steroids was done in 17 (28.3%) patients. Remission was maintained with Mesacol – 
57 (95%) along with oral steroids – 9 (15%) and azathioprine in 15 (25%) patients. Five 
patients required intravenous steroids for attaining remission and 3 received rectal steroid 
enema preparation for control of rectal symptoms. Nine (15%) were treated with steroids 
(Budesonide 3, Prednisolone 6) and 15 (25 %) steroid dependent / resistant patients with 
Azathioprine / Methotrexate.  Seventeen patients (28.3 %) had surgery at diagnosis or 
during follow up for intractable symptoms or for severe disease /failure to attain 
remission (12 for stricture resection/ stricturoplasty and 5 had right hemicolectomy). 
Twenty four (40%) patients received empiric anti-tuberculous therapy in the past. 
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Ulcerative colitis: 
The mean age of patients with UC was 37.6 + 14.6 years with majority being males 
(56%).  Diarrhoea was present in all patients while 46 (67.6 %) had abdominal pain. 
Extra intestinal manifestations in the form of scleritis/ episcleritis were present in only 4 
(5.8 %) patients.  One patient had pyoderma gangrenosum and 2 others had oral ulcers. 
Primary sclerosing cholangitis was noted in a patient. Thirty two (47.1 %) patients had 
pancolitis while 16 (23.5 %) had only proctosigmoiditis. Disease activity (Montreal) was 
moderate in 39.7 % patients, severe in 38.2 % and mild in 22.1 %.  All patients were 
treated with 5-ASA except the patients who underwent total proctocolectomy – 3 (4.4%). 
For remission induction, 37 patients received oral steroids (Budesonide 3; rest with 
prednisolone) and in 7 patients intravenous steroids were used. Twenty one patients 
(30.9%) received azathioprine for maintenance of remission.  
The clinical and laboratory profile of the two groups are shown in Table 1 & 2. 
 
Joint symptoms in Inflammatory Bowel Disease: 
Arthritis occurred in twenty- four patients (18 %); 11 with UC (16.1%) and 13 with CD 
(21.6%). Nine (37%) had simultaneous joint & IBD symptoms; in 2 (8.3 %) patients joint 
symptoms were present before the appearance of IBD symptoms, and the remaining 13 
(54.7%) had joint symptoms after the onset of IBD symptoms (Fig 3). It was therefore 
unusual for joint disease to precede manifestation of IBD symptoms. Both peripheral 
arthritis and sacroiliitis were found in five patients (3.9%). (Table 3).   
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Table : 3: Arthritis according to the extent of bowel involved and the type of 
arthritis in IBD. 
 
IBD 
(n=128) 
Crohns disease (n=60) Ulcerative colitis (n=68) 
 Colitis 
n = 29 
(48.3%) 
Ileitis 
n= 49 
(81.7%) 
Proctosigmoiditis 
n= 16 (23.5%) 
 
Left sided 
colitis 
n= 20 
(71.4%) 
Pancolitis 
n=32 
(47%) 
With joint 
involvement 
no. (%) 
24 (18.7) 
 
 
9 (31) 4 (8.1) 0 (0) 2 (10) 9 (28) 
Peripheral 
no. (%) 
12 (9.3) 
 
4 (13.7) 2 (4) 0 (0) 1 (5) 5 (15.6) 
Mixed 
no. (%) 
5 (3.9) 
 
1 (3.4) 2 (4) 0 (0) 0 (0) 2 (6.2) 
Axial 
no. (%) 
7 (5.4) 
 
4 (13.7) 0 (0) 0 (0) 1(5) 2 (6.2) 
 
In CD patients, arthropathy was significantly more common in patients with colitis (9/29) 
compared to those with ileitis alone (4/49) (Chi square test, P=0.0127). In UC patients, 
arthropathy showed a trend towards increasing joint involvement with increasing degree 
of colonic involvement (proctitis 0/16, left sided colitis 2/20 and pancolitis 9/32) with the 
Chi-square test for trend being significant (P=0.0271). 
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Fig: 3: Onset of IBD with relation to arthritis. IBD usually preceded arthritis, and 
less commonly occurred simultaneously with arthritis. 
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Peripheral joint involvement: 
Peripheral arthritis was found in twelve patients (9.3 % of total) and was not significantly 
different between UC (7/68) and CD (5/60). Eight of the 12 patients had colonic 
involvement (66.7%). Joint involvements tended to be monoarticular or oligoarticular. 
The most frequently affected joint was knee joint (14 patients) followed by ankle (7 
patients), elbow (4 patients), hip (3 patients), shoulder and wrist in 2 patients each. Only 
one of the 12 (8.3%) patients had more than 6 joints involved.  The baseline joint 
involvement is depicted in Figures 4 & 5. 
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Fig. 4: Number of joints involved in IBD patients with peripheral arthritis  
Number of joints involved in patients with peripheral arthritis
2
3
0
4
0
2
1
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
1 2 3 4 5 6 7
number of joints involved
nu
m
be
r o
f p
at
ie
nt
s 
in
vo
lv
ed
Number of patients
 
Fig 5: Pattern of peripheral joint involvement in IBD. Knee was most commonly 
involved, followed by ankle and elbow. 
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Axial joint involvement: 
Radiographic sacroiliitis was observed in eight (3 UC and 5 CD) of the 24 IBD patients 
with joint symptoms (33.3%) patients.  Spondyloarthropathy as described according to 
the ESSG criteria ( Gomariz et al) was diagnosed in six (1 UC and 5 CD) patients. All 
except one patient had colonic involvement in the spondyloarthropathy group (83.4%).  
The remaining one patient had isolated small bowel involvement. 
 
Joint symptoms in Ulcerative colitis: 
Seven (10.2% of total) patients had peripheral arthritis, 3 (2.3% of total) had axial 
arthropathy and another 2 had features of both axial and peripheral arthritis. Three 
patients had radiological sacroilitis (27.2%) and only one (9 %) had spondyloarthropathy. 
Nine of 32 UC patients (28%) with pancolitis had arthritis while none of the 16 patients 
with proctosigmoiditis had arthritis. On comparing patients with and without joint 
involvement, a higher CRP value, low serum albumin, low mean corpuscular volume & 
increased stool frequency were found in the UC patients with joint involvement (Table 
6). The higher the value the more is the chance of having joint involvement. The duration 
of illness and mean duration of symptoms prior to the diagnosis were not statistically 
significant between the 2 groups. The important baseline characteristics between the 2 
groups are as follows (table 4): 
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Table: 4 : Clinical characteristics of the patients with arthritis in ulcerative colitis: 
 
Total UC patients  
n= 68 (100%) 
With arthritis  
n = 11 (16.1%) 
Without arthritis 
n = 57 ( 83.9%) 
P value 
Age in Yr; mean + SD 34 + 14 38 +14.6 NS 
Sex M:F 6:5 32:25 NS 
Smoking Yes: No 1:10 1:56 NS 
Stool Frequency * mean + 
SD 
8.6 +3.4 5.3 +3.4 p < 0.05 
Mean corpuscular 
volume* 
67 + 23.7 78 + 15 p < 0.05 
C - reactive protein* 45.1 + 64.9 12.8 + 22.4 p < 0.05 
Serum albumin* 3.3 + 0.95 4 + 0.77 p < 0.05 
Hemoglobin 10.9 + 2.1 11 + 2.7 NS 
Values shown are absolute numbers or mean +SD. 
 
 
 
Joint symptoms in Crohn’s disease: 
In CD, arthritis occurred in 39% of the patients with colonic involvement (9 had arthritis 
of total of 29 with colonic involvement) but in only 4 of 49 CD patients with small bowel 
involvement had arthritic symptoms (8.2%). This was statistically significant (P=0.0127).  
Spondyloarthropathy was noted in 4 (6.6%) of the CD patients while peripheral arthritis 
was noted in 6 (10%) patients. Four patients had features of both axial and peripheral 
arthritis. On cross tabulating using Mann Whitneys test and Fischers exact t test, elevated 
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CRP was the only parameter found to be significantly correlated with the joint 
involvement. Low serum albumin, high ESR and greater height were approaching 
significance though are found to be not significant statistically. 
 
Table: 5: Clinical characteristics of the patients with arthritis in Crohns Disease: 
 
Total CD patients  
n= 60 (100%) 
With arthritis  
n = 13 (21.6 %) 
Without arthritis 
n = 47 (78.4%) 
P value 
Age in Yr; mean + SD 36.9 + 9.6 38.5 +16.6 NS 
Sex M:F 9:4 31:16 NS 
Height in cms 156.4 + 10.3 153.5 + 8.6 NS 
Abdominal pain yes: no 10 :3 39:8 NS 
Diarrhoea 8:5 25 :22 NS 
Smoking Yes: No 0: 13 5:42 NS 
Hemoglobin mean + S.D 10.8 +1.3 10.6 + 2.7 NS 
Mean corpuscular volume 77.2 +10 77.2 + 21 NS 
C reactive protein* 62 + 56.5 14.6 + 23.4 0.0047 
Serum albumin 3.3 +1 3.6 +1.1 NS 
Erythrocyte sedimentation 
rate 
44 + 27 37.7 + 29.7 NS 
* p <0.05 using Mann-Whitney test 
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Real time PCR analysis: 
 
Average bacterial quantifications in each patient group are summarized in Table 6. The 
results were then compared to IBD with joint and IBD without joint groups (Fig. 1) 
 
Table 6: Fecal microbial flora in IBD patients with and without joint disease  
Log10 values (mean +SD) are shown.: 
 
 
The most prevalent phyla were Bacteroidetes and Bifdobacterium in both groups and 
no commensal was significantly different between the 2 groups. Quantitative 
molecular characterization of specific classes of the bacterial flora - Bacteroides, 
Eubacterium, Clostridium, bifidobacteria, and lactobacilli revealed no difference of 
flora between the IBD patients with and without joint involvement. 
 
Bacteria IBD Without 
Joints 
IBD with Joints P Value 
Total Bacteria 9.2 ± 0.071 9.3 ± 0.110  0.5371 
Enterobactericeae  8.1 ± 0.110  8.6 ± 0.260 0.0772 
Bifidobacterium genus 8.2 ± 0.130 8.3 ± 0.220 0.8734 
Clostridium coccoides  7.102 ± 0.1767  6.557 ± 0.3796  0.1067 
Bacteroidetes  9.2 ± 0.150 9.2 ± 0.280 0.9658 
Lactobacillus group 5.748 ± 0.1301 5.888 ± 0.1841 0.6383 
Desulfovibrio genus 6.632 ± 0.1024  6.539 ± 0.1607 0.8545 
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Table 7. IBD: Fecal microbial flora in UC compared to CD patients.  
Log10 values (mean +SD) are shown.  
 
 
 
Between the two CD and UC groups, Enterobactericeae was noted to be more prevalent 
in UC than in CD (P<0.05). Rest of the commensals were similar between the 2 groups.  
In subgroup analysis of CD by joint involvement there was no commensal identifying the 
propensity for joint involvement (Table 8). 
Table 8. CD: Fecal microbial flora in CD patients with and without joint 
involvement. Log10 values (mean +SD) are shown.  
 
 
 
 
 
 
 
Bacteria CD UC P Value 
Total Bacteria 9.2 ± 0.09 9.39 ± 0.10 0.21 
Enterobactericeae  8.11 ± 0.16 8.53 ± 0.17 0.05 
Bifidobacterium genus 8.23 ± 0.19  8.29 ± 0.17 0.74 
Eubacterium 6.88 ± 0.24 7.26 ± 0.23 0.20 
Bacteroides  9.13 ± 0.19 9.53 ± 0.22 0.20 
Lactobacillus group 5.92 ± 0.17 5.82 ± 0.19 0.89 
Desulfovibrio genus 6.68 ± 0.16 6.73 ± 0.14 0.70 
Bacteria CD Without Joints CD with Joints P Value 
Total Bacteria 9.16 ± 0.120 9.34 ± 0.13 0.23 
Enterobactericeae  6.85 ± 0.280 6.99 ± 0.47 0.95 
Bifidobacterium genus 8.18 ± 0.220 8.45 ± 0.30  0.6677 
Clostridium coccoides 
groups 
7.102 ± 0.1767  6.557 ± 0.3796  0.2029 
Bacteroidetes  9.2 ± 0.150 9.2 ± 0.280  0.9462 
Lactobacillus group 5.748 ± 0.1301  5.888 ± 0.1841  0.5377 
Desulfovibrio genus 6.632 ± 0.1024  6.539 ± 0.1607 0.6269 
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Table: 9: UC: Fecal microbial flora in UC patients with and without 
joints Log10 values (mean +SD) are shown.  
 
 
On comparison of bacterial commensals in stools of patients of  ulcerative colitis with 
and without joint disease, Enterobactericeae were found in a higher number in joint group 
and Clostridium coccoides were found in higher number in the group without joint 
involvement and were statistically significant (p<0.05). 
 
 
 
 
UC With and without joints: Quantification of dominant and subdominant bacteria
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Bacteria UC Without Joints UC with Joints P Value 
Total Bacteria 9.408 ± 0.1172  9.336 ± 0.1810  0.9337 
Clostridium coccoides 
groups 
7.516 ± 0.2452  5.993 ± 0.5927  0.0108 
Enterobactericeae 8.413 ± 0.1984  9.175 ± 0.2339  0.0410 
Bacteroidetes 9.599 ± 0.2479  9.168 ± 0.4994  0.4881 
Bifidobacterium genus 8.322 ± 0.2026  8.151 ± 0.3141  0.4881 
Lactobacillus group 5.738 ± 0.2178  6.282 ± 0.3325  0.1475 
Desulfovibrio genus 6.800 ± 0.1667  6.413 ± 0.3136  0.4924 
 54
 
 
CD Vs UC - Quantification of dominant and subdominant bacteria
in the fecal microbiota
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CD With and without Joints: Quantification of dominant and subdominant
bacteria
in the fecal microbiota
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Disability following joint involvement in IBD: 
Nine of the 24 patients had active joint complaints at the time of examination and the rest 
of the 16 had joint symptoms in the immediate 5 years of follow up. Five of 16 patients 
had severe joint involvement with restriction which resolved with therapy. One of them 
also had avascular necrosis of the hip (steroid related) which needed a total hip 
replacement. 
 The examined patients had normal chest wall expansion at 4th intercostal space as well as 
occiput to wall distance. Four of them had Achilles enthesitis. Mean PGA (patients 
general assessment of the activity) of joints in the past 1week was 40 with a range from 
10 to 80 on a 100 point scale with minimum score means less disease activity. The Bath 
ankylosing spondylitis global score (BAS-G) which denotes global health in the past 1 
week to 6 months in a 10 point scale (maximum is severe disease activity) of the involved 
patients was 6.5.The Bath ankylosing  spondylitis disease activity index in past 1 week 
(BASDAI)  which comprises of 6 questionnaire each in a 10 point scale and the Bath 
ankylosing functional index in past 1 month (BASFI) comprising 10 activity questions in 
10 point scale with the maximum being severe disease activity and both had a mean value 
of  2.5 out of 10 in the study group. The Bath ankylosing spondylitis metrology index 
(BASMI) which includes objective involvement of axial joints in a 0 – 10 point scale 
with 10 being maximum restriction revealed none of the patients had a score of more than 
one. The subjective component of joint activity was higher than the objective 
involvement in the study group. 
For the peripheral joints, disease activity score (DAS) with the involved joints 
assessed for tenderness, limitation and swelling revealed 15 joints to be involved. 
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Arthralgias and non deforming arthritis were noted in 4 each and none had deforming 
arthritis.  
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                                                                Discussion 
 
 
 
 
Ever since the first description of joint involvement with UC and CD in 1895 and 1930, 
several reports were published on this concept. The inter link between the gut and joint 
needs to be studied for determining the pathophysiology between the two diseases. The 
current opinion favors the concept of enteric organisms acting as bowel triggers in a 
disease susceptible individual (Jan tore gran et al).  
To evaluate the prevalence of arthritis and the bacterial flora associated with IBD in 
India, we prospectively studied one hundred and twenty-eight patients with IBD, 68 with 
ulcerative colitis (UC) and 60 with Crohn's disease (CD). The clinical characteristics of 
arthritic flares are similar in both UC and CD. Palumbo et al reviewed the articular 
manifestations of 121 patients with IBD and found no distinguishing characteristics 
between the arthritis that is seen in CD and that seen in UC. (Gravallese et al). In our 
study arthritis was noted in twenty- four IBD patients (18 %); 13 with CD (21.6%) and in 
11 with UC (16.1%). Thirteen (54.7%) patients had joint symptoms after the onset of 
IBD symptoms which correlate with the previous studies from other countries 
(Gravallese et al).  
The pattern of joint involvement was common in both UC and CD groups. 
Peripheral arthritis alone was noted in 12 (9.3%) patients, peripheral arthritis along with 
axial involvement in 5 (3.9%), and axial involvement alone in 7 (5.4%) patients which 
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were similar to the review of prevalence of joint symptoms in IBD patients by Jan tore 
gran et al. 
Arthritis in CD patients was associated significantly more commonly with colonic 
disease (9/29) compared to ileal disease (4/49). Arthritis in UC patients showed an 
association with increasing length of colonic involvement, being 0% in proctitis, 10 % in 
left sided colitis and 28 % in pancolitis. The most frequently affected peripheral joint was 
knee joint (14 patients) followed by ankle (7 patients), The most frequently affected joint 
was knee joint (14 patients) followed by ankle (7 patients) and radiographic sacroiliitis 
was observed in eight of the 24 IBD patients. The bacterial answer for this pattern of 
involvement was proposed in earlier reviews as the possibility of diseased bowel 
providing the immunological stimulus for the occurrence of arthritis along with higher 
bacterial loads in the distal gut. (Gravallese et al). Severe and extensive forms of UC 
correlated with more complicated joint involvement. In UC patients with pancolitis, 
arthritis and polyarthritis were observed significantly more often as noted by Dorofeyev 
et al.. Similar finding was observed in our study. 
In UC, joint involvement was associated with lower albumin, higher ESR, higher 
CRP, increasing stool number, all indicating increased disease activity. In CD, joint 
involvement was associated with higher CRP, but not with any other index of disease 
activity. The sub group analysis was not done as the study was not powered adequately 
for sub-group analysis.   
IBD is caused by a genetically determined defect in the down-regulation of inflammation 
driven by ubiquitous antigens. Luminal anaerobic bacterial antigens are the stimuli in 
Crohn's disease, but ulcerative colitis may also be caused by functionally abnormal 
 59
aerobic bacteria or primary defects in epithelial cell physiology (Sartor et al). In 90 
(94.7%) UC patients with joint EIM, two or more types of facultative bacteria occurred. 
In patients with arthritis, bacterial associations such as Staphylococcus-Klebsiella, 
Staphylococcus-Proteus or Staphylococcus-Klebsiella-Proteus were observed more often. 
In all patients with joint manifestations, these facultative flora quantities were 
significantly higher than in the healthy population and UC patients without EIM (A.E. 
Dorofeyevet al). In our study we studied the commensals alone IBD with and without 
joint involvement and found that enterobacteriaceae were higher (P< 0.05 by Mann 
whitneys) in IBD with joint symptoms. Rest of the commensals studied was common 
between the 2 groups.  
   The subjective component of axial joint activity (BAS – G; BASDAI) was higher than 
the objective involvement (BASMI, BASFI) in the study group. The peripheral arthritis is 
migratory and non deforming and distinct from the peripheral arthritis is an arthritis 
involving large joints seen specifically in patients with spondylitis. The hips and 
shoulders are specifically involved and to a lesser extent the knees. Hips and shoulders 
may be permanently damaged as noted in a single patient with hip replacement.  
(Gravallese et al) 
In UC, joint involvement was associated with lower albumin, higher ESR, higher 
CRP, increasing stool number, all indicating increased disease activity. In CD, joint 
involvement was associated with higher CRP, but not with any other index of disease 
activity. 
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In a study of 319 UC patients from Ukraine, bacterial flora was compared between the 
patients with and without joint involvement.  Patients with joint EIM, severe dysbiosis 
with a facultative bacteria association were found. Staphylococcus , Klebsiella and 
Proteus were more commonly identified in patients with arthritis (Dorofeyev et al.,). In 
our study we did not study the other facultative organisms. The study was designed to 
observe the pattern of commensals in joint involvement in Indian IBD patients. It is now 
commonly considered that the commensal flora of the intestine falls into three categories 
– those bacterial classes or groups that are aggressive (including Bacteroides, 
Helicobacter species, Enterococcus fecalis, and pathogenic Escherichia coli; those 
bacterial groups that are protective including Lactobacillus and Bifidobacterium species 
(which are used as “probiotics”) and those that are neutral which include the majority of 
Escherichia coli (Glenn Gibson et al). In this study, differences were noted in the 
quantitative bacterial flora between UC patients with and without arthritis, pointing to a 
possible association between such bacterial shifts (dysbiosis) and arthritis. On 
comparision of bacterial commensals in stools of patients of  ulcerative colitis between 
joint and without joint groups, enterobactericeae were found in a higher number in 
patients with joint involvement whereas Clostridium coccoides were found in higher 
number in the group without joint involvement and were statistically significant (p<0.05). 
Enterobacteriaceae may be deleterious to the human host if they get out of alance. 
Similarly, reductions in level of Clostridium coccoides may be associated with greater 
inflammation. This cluster of bacteria ferments carbohydrates to short chain fatty acids, 
including butyrate. These short chain fatty acids provide fuel energy to the colonic 
epithelium, but importantly they also ameliorate inflammation through suppression of 
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HSP70-dependent innate immune pathways. Short chain fatty acids such as butyrate also 
reduce colonic permeability thereby reducing the non-specific absorption of antigens 
from the intestine. In subgroup analysis of CD by joint involvement there was no 
commensal identifying the propensity for joint involvement. Between the two CD and 
UC groups, Enterobactericeae was noted to be more prevalent in UC than in CD 
(P<0.05). Rest of the commensals were similar between the 2 groups. The most prevalent 
phyla were Bacteroidetes and Bifdobacterium in both groups and no commensal was 
significantly different between the 2 groups. Quantitative molecular characterization of 
specific classes of the bacterial flora - Bacteroides, Eubacterium, Clostridium, 
bifidobacteria, and lactobacilli revealed no difference of flora between the IBD patients 
with and without joint involvement.  
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                                                  Conclusions 
 
 
¾ This is the largest study to date, comparing the bacterial flora in stool in 
inflammatory bowel disease (IBD) patients with and without joint involvement. 
¾ Prospective study of one hundred and twenty-eight patients with IBD, 68 with 
ulcerative colitis (UC) and 60 with Crohn's disease (CD).  
¾  CD patients had abdominal pain (82%) as the commonest presentation followed 
by diarrhoea (55%). Diarrhoea (100%) was the commonest presenting symptom 
among UC patients followed by blood in stool (97%).  
¾ Presence of abdominal pain, diarrhoea, blood in stools, fever, intestinal 
obstruction and past history of appendicectomy significantly differentiated 
between the CD and UC groups. 
¾ Disease activity (Montreal) was moderate in 39.7 % patients, severe in 38.2 % 
and mild in 22.1 % in UC patients.  In CD patients’ disease severity as assessed 
using the Harvey Bradshaw score showed the majority (59%) of patients had 
moderate to severe disease. 
¾  Arthritis was noted in twenty- four IBD patients (18 %); 13 with CD (21.6%) and 
in 11 with UC (16.1%). Arthritis was equally common in CD and UC groups. 
Thirteen (54.7% ) patients had joint symptoms after the onset of IBD symptoms 
¾  Peripheral arthritis alone was noted in 12 patients, peripheral arthritis + axial 
involvement in 5, and axial involvement alone in 7 patients 
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¾ Arthritis in CD patients was associated significantly more commonly with colonic 
disease (9/29 - 31%) compared to ileal disease (4/49 - 8.1%). 
¾ Arthritis in UC patients showed a trend for association with increasing length of 
colonic involvement, being 0% in proctitis, 10% (2 of 20 patients) in left sided 
colitis and 28% (9 of 32 patients) in pancolitis. 
¾  The subjective component of axial joint activity (BAS – G; BASDAI) was higher 
than the objective involvement (BASMI, BASFI) in the study group. The most 
frequently affected joint was knee joint (14 patients) followed by ankle (7 
patients) and radiographic sacroiliitis was observed in eight  of the 24 IBD 
patients 
¾  In UC, joint involvement was associated with lower albumin, higher ESR, higher 
CRP, increasing stool number, all indicating increased disease activity. 
¾ In CD, joint involvement was associated with higher CRP, but not with any other 
index of disease activity. 
¾ The most prevalent phyla were Bacteroidetes and Bifdobacterium in both groups. 
Enterobacteriaceae numbers were slightly (but significantly) higher in patients 
with UC than in CD.  In UC patients, joint involvement was associated with 
higher Enterococcus species and lower Clostridium coccoides cluster, suggesting 
a dysbiosis in these patients. 
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 PROFORMA FOR JOINT SYMPTOMS IN IBD 
 
Patients Name:                                                                CMCH No:  
Contact Address:                                                             Occupation: 
 Income/month:          Telephone: 
 E Mail: 
 
 
1. Age in years: 
2. Year of birth: 
3.  Gender: 
4. Mother Tongue: 1.Tamil  2.Telugu  3.Malayalam  4.Kannada 
                                5.Bengali    6.Oriya   7.Hindi          8.Others 
5. State Of Origin: 
6. Weight (Kg): 
7. Height (cm): 
8. Mid arm circumference: 
9. Religion:   1.Hindu   2. Muslim 3. Christian       4.Other 
10. Education: 1. None   2. I- V Std   3. VI-X Std    4.Plus 2 
                        5. Graduate                        6. Post Graduate 
Patient History: 
1. At what age did the symptoms appear? 
2. At what age was the disease diagnosed? 
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3. Which year was diagnosis first made? 
4. Where was the diagnosis made? 1.CMC  2.Local hospital  3.Other 
Have you ever had the following symptoms in relation to your illness? 
5. Abdominal Pain    1.Yes               2.No 
6. Diarrhoea      1.Yes    2.No 
7. Blood in Stools    1.Yes    2.No 
8. Urgency      1.Yes    2.No 
9. Incontinence      1.Yes    2.No 
10. Tiredness      1.Yes    2.No 
11. Fever        1.Yes    2.No 
12. Intestinal Obstruction     1.Yes     2.No 
13. Have you lost weight?   1. Nil      2. <5Kg       3. 5-10Kg      4.>10Kg      
14. What is the frequency of your stools now?   
15. Have you had anal canal lesions: 1. Fissure    2. Ulcers    3.Fistulae 
16. Have you had painful boils in legs/body:       1.Yes               2.No 
17. Have you had painful redness of eyes:           1.yes                2.No 
18. Any other problem:     
Past Medical History & Family and Personal History: 
19. Diabetes mellitus     1. Yes    2.No 
20. Hypertension       1.Yes    2.No 
21. Pulmonary tuberculosis               1. Yes   2.No 
22. Extra Intestinal tuberculosis                     1.Yes             2.No 
23. Were you ever diagnosed to have intestinal TB?    1. Yes          2.No 
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24. Have you had appendicectomy?   1. Yes           2.No 
25. If yes, was it done for acute abdominal pain?            1. Yes         2.No 
26. Have you had any other operation on abdomen?       1. Yes         2.No 
27. Has any other family member had IBD?   1. Yes           2.No 
28. Do you currently smoke cigarettes/beedies? 
      1. No           2. <7 per week           3. 7/wk to 10/day        4.> 10/day 
29. In the past did you smoke cigarettes/beedies? 
      1. No           2. <7 per week           3. 7/wk to 10/day        4.> 10/day 
30. Did you chew tobacco alone or with paan?              1. Yes           2.No 
31. Do you take alcohol drinks? 
    1. Teetotaler   2. Social drinker   3.Moderate drinker    4.Heavy drinker 
32. What diet do you take? 
      1. Strict Vegetarian    2.Eggs also       3.Non-vegetarian 
 
Medical treatment: 
33. Have you ever used aminosalicylates in the past?      1. Yes         2.No 
34. Have you ever used oral steroids in the past?              1. Yes       2.No 
35. Have you ever used rectal steroids in the past?           1. Yes       2. No 
36. Have you ever used IV steroids in the past?                1.Yes        2.No 
37. Are you currently using aminosalicylates?  1.yes    2.no   3.cannot say 
38. Are you currently using steroids (any form)? 1.yes  2.no  3.cannot say 
39. Are you currently using azathiprine/immunosuppressant?  
                                                                          1.yes    2.no   3.cannot say 
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40. Have you received drugs for TB in the past? 1.yes   2.no  3.cannot say 
41. Are you currently taking drugs for TB?        1.yes   2.no   3.cannot say 
42. Joint symptoms onset with IBD? 
      1. Simultaneous     2.Before GI symptoms        3. After GI symptoms 
43. Relation with the activity of GI symptoms with Joint symptoms? 
     1. Abdominal pain 2.Diarrhoea 3.Blood in stools 4. Perianal disease   
44.Laboratory findings: 
Test Date/Finding Report/Biopsy 
Hb (g/dl)   
MCV (fL)   
ESR (mm/hr)   
CRP   
S Albumin   
S Alk.Phos   
Stool Parasites x 2   
Endoscopy   
Colonoscopy   
BMFT/CECT Abdomen   
X Ray of joints   
Sacroileitis   
RA/HLA B27/ASCA   
Bowel Flora   
NOD 2 Mutation   
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Date Of assessment:   45. Montreal classification for CD:  
Age at diagnosis: radiology/endoscopy/pathology/surgery 
A1: Below 16 years     A2: Between 17 - 40 years               A3: Above 40 yrs 
Maximum extent of the disease: small and large bowel examination needed: 
L1: Ileal (no colon)           L2: Colonic                               L3: Ileocolonic              
L4: Isolated upper disease (L4 –Modifier – Be added to L1-L3 when concomitant upper 
gastrointestinal disease is present) 
Behaviour: 
B1: Non- Stricturing, non-penetrating     B2: Stricturing (obstructive) 
 B3: Penetrating (fistula,mass,abscesses,ulcers) 
P: Added to B1-B3 when concomitant perianal disease is present 
Severity for CD:  Harvey Bradshaw Index (HBI, Simple Index) 
1 General well being (0: very well, 1: slightly below par, 2: poor, 3: very poor,      4:    
terrible) 
2 Abdominal pain (0: none, 1: mild, 2: moderate, 3: severe) 
3 Number of liquid stools daily: 
4 Abdominal mass (0: none, 1: dubious, 2: definite, 3: definite and tender) 
5 Complications: arthralgia, uveitis, erythema nodosum, apthous ulcer, pyoderma 
gangrenosum, anal fissure, new fistula, Abscess (score 1 per item) 
 
46. Total HBI score:                   HBI Score: (<4, mild; 5–8, moderate; >9, severe)  
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Date Of assessment: 
 
45.Montreal Classification of Extent of Ulcerative colitis 
 
E1(Procto - Sigmoiditis ): Ulcerative Proctitis: Involvement limited to rectum (proximal 
extent of inflammation is distal to the recto sigmoid junction 
 
E2: Left Sided UC (Distal UC): Involvement limited to a proportion of the colorectum 
distal to the splenic flexure 
 
E3: Extensive UC (Pan Colitis + back wash Ileitis): Involvement extends proximal to the 
splenic flexure 
 
46.Montreal Classification of severity of Ulcerative Colitis 
 
S0- Clinical Remission- Asymptomatic 
 
 
S1- Mild UC-Passage of 4/fewer stools /day (with or without blood), absence of any 
systemic illness and normal inflammatory markers (ESR) 
 
S2- Moderate UC- More than 4 stools per day but with minimal signs of systemic toxicity 
 
 
 
S3- Severe UC-At least 6 bloody stools daily, pulse rate of at least 90 beats/min, 
temperature of at least 37.5C,Hb <10.5g/100mL and ESR of at least 30mm/hr  
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Musculo Skeletal Manifestations 
 
IBD Symptoms Duration:     Joint symptoms Duration 
 
Chest wall expansion at 4th intercostals space:  
 
Occiput to wall distance: 
 
Enthesitis: 
          Achilles tendinitis: Pain/difficulty in walking/swelling/tenderness for 1 month 
          Plantar fasciatis:  Pain/difficulty in walking/swelling/tenderness for 1 month 
 
Dactylitis: sausage digit: + / - 
 
Peripheral Arthritis: 1/more painful/painfully restricted swollen joints for at least 3 
months 
 
ESSG entry criteria for SpA: 1 OR 2 
• Inflammatory back pain — Inflammatory  If 4 OF 5 : ( walk at night for pain)  
                       - Age: < 40 years + / -  
                       - Onset: Insidious + / - 
                       - 3 months Duration + / -  
                       - Morning Stiffness + /-  
                       - Improvement with exercise + / - 
• Asymmetrical synovitis — Predominantly  lower limbs 
Warmth/difficulty in walking/swelling/reduction in both active and passive range of 
motion Worse after a period of rest +/ -  
Additional criteria — any one of the above is positive,  
      -  Positive family history of psoriasis/ankylosing spondylitis 
      - Psoriasis  
      - Inflammatory bowel disease  
      - Urethritis, cervicitis, or acute diarrhea within one month before arthritis  
      - Buttock pain alternating between buttocks  
      - Enthesopathy  
      - Plain film radiographic evidence of sacroileitis  
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* GENERAL HEALTH or patients’ global assessment of disease activity: 
How active your arthritis been during the last 7 days? 
(PATIENTS ASSESSMENT IN MM) 
 
NO ACTIVITY ----------------------------------Æ  HIGHEST ACTIVITY POSSIBLE 
 
 
0 ----- 10 ----- 20 ----- 30 ----- 40 ----- 50 ----- 60 ----- 70 ----- 80 ----- 90 ----- 100 
 
 
 
 
AXIAL  JOINTS : BAS-G; BASDAI ; BASFI ; 
BASMI 
 
The Bath Ankylosing Spondylitis Global Score (BAS –G)   
     
                  
  Total/10 
1 How have you been over the last week? 
VERY GOOD ---------------------------------------------------VERY BAD 
 
 
2 How have you been over the last six months? 
VERY GOOD ---------------------------------------------------VERY BAD 
 
 
 
     TOTAL OUT OF 20 
 
 
                                            TOTAL / 2 (BAS-G SCORE)  
                                                
 
 
 
BASDAI: 
 
A. If you are currently taking medication for your AS, please give the name and 
dose that is on the bottle/packet. 
B. Please mark on the line below to indicate the effectiveness of the medication in 
relieving your symptoms  
NO EFFECT ----------------------------------------------- VERY EFFECTIVE 
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THE BATH ANKYLOSING SPONDYLITIS DISEASE 
ACTIVITY INDEX (BASDAI) 
 
Please draw a mark on each line below to indicate the level of ability with each of the 
following activities during the PAST WEEK(0-10 points each) 
 
 
1 How do you describe the overall level of fatigue/tiredness you have experienced? 
 NONE ---------------------------------------------------------------- VERY SEVERE 
 
 
2 How would you describe the overall level of AS neck, back or hip pain you have had? 
NONE ---------------------------------------------------------------- VERY SEVERE 
 
 
3 How would you describe the overall level of pain/swelling in joints other than neck, 
Back or hips you have had? 
NONE ------------------------------------------ VERY SEVERE 
 
 
4 How do you describe the overall level of discomfort you have had from any areas tender to touch 
or pressure? 
NONE ------------------------------------------ VERY SEVERE 
 
5 How do you describe the overall level of discomfort you have had from the time you wake up? 
NONE ------------------------------------------ VERY SEVERE 
 
 
6 How long does your morning stiffness last from the time you wake up? 
0 --------- 1/2 --------- 1 --------- 1 1/2 --------- 2 or more hours 
 
 
                                                                                                         MEAN OF 5&6  
            TOTAL OF 1 TO 4 ADDED TO MEAN OF 5&6 (TOTAL OUT OF 50)  
 TOTAL / 5 (BASDAI SCORE)
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THE BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX 
(BASFI) 
Please draw a mark on each line below to indicate the level of ability with each of the 
following activities during the LAST MONTH (0-10 points each) 
 
1 Putting on your socks or tights without help or aids? 
Easy--------------------------------------------------------------Impossible 
 
 
2 Bending forward from the waist to pick up a pen from the floor without 
an aid? 
Easy--------------------------------------------------------------Impossible 
 
 
3 Reaching up to a high shelf without help or aids? 
Easy--------------------------------------------------------------Impossible 
 
 
4 Getting out of an arm less dining chair without using your hands or any 
help? 
Easy--------------------------------------------------------------Impossible 
 
 
5 Getting off the floor – without help –from lying on your back? 
Easy----------------------------------------------------------------Impossible 
 
 
6 Standing unsupported for 10 minutes without discomfort? 
Easy---------------------------------------------------------------Impossible 
 
 
7 Climbing 12-15 steps without using the hand rails or walking aids? 
Easy---------------------------------------------------------------Impossible 
 
8 Locking over your shoulder without turning your body? 
Easy---------------------------------------------------------------Impossible 
 
 
9 Doing physically demanding activities (e.g., physio exercises) 
Easy---------------------------------------------------------------Impossible 
 
 
10 Doing a full day activities at home or at work? 
Easy---------------------------------------------------------------Impossible 
 
 
 TOTAL OUT OF 100  
 TOTAL/10 (BASFI SCORE)  
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THE BATH AS METROLOGY INDEX (BASMI) 
 
Measure 
* Mean of right and left 
Mild 
0 
Moderate 
1 
Severe 
2 
Patients 
score 
*Lumbar side flexion 
Stand to a wall, feet 30cm apart, hands 
by side, tip of middle finger to the floor 
& side flexion and  measure 
>10 cm 5-10cm <5 cm 
 
Lumbar flexion (modified Schober) 
Feet 30 cm apart, line midway between 
iliac crests, a point 10cm above and 
another 5 cm below – gap of 15cm; 
Flexion and measure – increase is noted
>4 cm 2- 4 cm <2 cm 
 
*Tragus to wall distance 
Back to  wall, feet 30 cm apart, side of 
face to wall and the distance of tragus to 
wall 
 
<15 cm 15-30 cm >30 cm 
 
Intermalleolar distance 
Supine, knees extended, legs apart as far 
as possible, distance between the medial 
malleoli 
>100 cm 70 – 100cm <70 cm 
 
*Cervical Rotation 
Supine, Forehead in horizontal position, 
head rotation as far as feasible and 
goniometry 
> 70 cm 20 – 70 cm <20 cm 
 
Patient BASMI score - Total    
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PERIPHERAL JOINTS  
 
DISEASE ACTIVITY SCORE - JOINT COUNT 
 
 
Joint  Right   Left  
 Tenderness Swelling Limitation Tenderness Swelling Limitation 
Shoulder       
Elbow       
Wrist       
MCP       
PIP       
DIP       
Hip       
Knee       
Ankle       
MTP       
PIP       
DIP       
Total       
 
 
 
 
 
 
 
JOINT COUNT: Axial: 
 
 
Joint Tenderness Swelling Limitation 
Cervical    
Temporo mandibular    
Sternoclavicular    
Acromioclavicular    
Total    
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PATIENT’S INFORMATION SHEET AND CONSENT 
 
Study title:  Joint manifestations in IBD patients and the relation of the bowel flora 
Principal Investigator:  Dr. Avinash Balekuduru 
INFORMATION SHEET (to be read by, or explained to the patient) 
Inflammatory bowel disease (IBD) causes intestinal symptoms and may also sometimes 
affect the joints. 
Dr. Avinash is doing this study in order to find out what is the connection between the 
intestinal symptoms and the joint symptoms, and to see if the germs in the intestine or the 
patient’s genes are responsible for these symptoms. 
The study involves the normal clinical examination including a detailed examination of 
the joints. It also involves giving a 10 ml sample of blood for genetic testing and giving a 
stool sample for studying the germs in it. 
All other tests are only done for your clinical care.  
The results of the tests done in connection with the study may directly benefit you. They 
are likely to indirectly benefit other patients with the disease. 
The results of the tests will be kept confidential and there will be no direct link of the test 
report with your hospital records. 
You are free to not participate in this study if you do not so wish. 
CONSENT 
I hereby provide my consent for the above research study and to give the necessary 
information and samples. 
I also provide my consent for the blood and stool sample to be preserved for additional 
research for a period of five years without my further approval, under the condition that 
the results will be kept anonymous and not linked to me. 
 
Name:      Hosp. No:    Study No: 
Date:     Signature: 
 
Witnessed by:     (Name     ) 
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                                                  ABSTRACT 
 
 
TITLE OF THE ABSTRACT:  Joint manifestations in Inflammatory Bowel Disease 
(IBD) – A cross-sectional study with special emphasis on relationship of gut flora to 
bowel and joint disease 
DEPARTMENT: Gastrointestinal Sciences 
NAME OF THE CANDIDATE: Dr Avinash B 
DEGREE AND SUBJECT: Doctor of Medicine (D.M) Medical Gastroenterology 
NAME OF THE GUIDE: Dr B S Ramakrishna. DM, Professor and Head, Clinical 
Gastroenterology and Hepatology, Department of Gastrointestinal Sciences, Christian 
Medical College, Vellore 
OBJECTIVES : To assess the frequency and pattern of joint involvement in 
inflammatory bowel disease and to determine whether joint involvement is associated 
with a dysbiosis of the intestinal microbial flora  
METHODS:  Consecutive patients with ulcerative colitis (UC) or Crohn's disease (CD) 
were prospectively interviewed and examined by the principal investigator and clinical 
details and laboratory results noted. The pattern of joint involvement and severity was 
independently confirmed by a specialist rheumatologist. Radiographs of the involved 
peripheral joints, sacroiliac joints and spine were obtained. DNA was extracted from 
stool samples and real time PCR targeting 16S ribosomal DNA was used to quantitate 
specific classes of “beneficial” (Clostridium coccoides, bifidobacteria, and lactobacilli) 
and “aggressive” (Bacteroides, Enterobacteriaceae, Enterococcus) bacterial flora. Disease 
activity and bacterial counts were compared between patients with and without joint 
involvement.  
RESULTS : Sixty eight patients with ulcerative colitis (UC) and 60 with Crohn's disease 
(CD) were included in this prospective study. Arthritis was noted in twenty- four IBD 
patients (18 %); 13 with CD (21.6%) and in 11 with UC (16.1%).  Peripheral arthritis 
alone was noted in 12 patients, axial involvement alone in 7 and rest had mixed pattern. 
The most prevalent phyla in IBD patients were Bacteroidetes and Bifdobacterium.. 
Enterobacteriaceae were significantly higher in patients with UC than in CD.  In UC 
patients, joint involvement was associated with higher Enterococcus species and lower 
Clostridium coccoides  suggesting a dysbiosis in these patients. 
 
 
 
 
 
 
